Zoledronic acid
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Cervical Neoplasms
Conditions
Uterine Cervical Neoplasms
Trial Timeline
Aug 1, 2009 → Mar 1, 2010
NCT ID
NCT00966992About Zoledronic acid
Zoledronic acid is a phase 2 stage product being developed by Novartis for Uterine Cervical Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT00966992. Target conditions include Uterine Cervical Neoplasms.
What happened to similar drugs?
4 of 18 similar drugs in Uterine Cervical Neoplasms were approved
Approved (4) Terminated (7) Active (8)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01197300 | Phase 3 | Completed |
| NCT01087008 | Approved | Completed |
| NCT01004510 | Phase 2 | Terminated |
| NCT00909961 | Phase 3 | Completed |
| NCT00966992 | Phase 2 | Terminated |
| NCT00760370 | Phase 2 | Completed |
| NCT00774020 | Approved | Completed |
| NCT00740129 | Approved | Completed |
| NCT00745485 | Approved | Completed |
| NCT00477217 | Phase 2 | Withdrawn |
| NCT00622505 | Approved | Completed |
| NCT00982124 | Phase 3 | Completed |
| NCT01218035 | Approved | Completed |
| NCT00434447 | Approved | Completed |
| NCT00424983 | Phase 1 | Completed |
| NCT00391950 | Phase 3 | Terminated |
| NCT00361595 | Pre-clinical | Completed |
| NCT00334139 | Approved | Completed |
| NCT00391690 | Approved | Completed |
| NCT00375427 | Phase 3 | Completed |
Competing Products
20 competing products in Uterine Cervical Neoplasms